Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06125327
PHASE2/PHASE3

SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

Sponsor: Guangzhou JOYO Pharma Co., Ltd

View on ClinicalTrials.gov

Summary

Evaluating Sufenidone (SC1011) in IPF patients for efficacy and safety. Includes screening, treatment, and follow-up, with FVC decline and health checks.

Official title: A Randomized, Double-blind, Placebo-controlled Phase II/III Trial Evaluating the Efficacy and Safety of Sufenidone (SC1011) Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF).

Key Details

Gender

All

Age Range

40 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

210

Start Date

2023-06-06

Completion Date

2027-12-31

Last Updated

2024-11-19

Healthy Volunteers

No

Interventions

DRUG

SC1011

Patients receive the dose of SC1011 tablets orally twice daily (b.i.d) for 52 weeks.

DRUG

Placebo comparator

Patients receive the dose of placebo orally twice daily (b.i.d) for 52 weeks.

Locations (1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China